Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

3rd Quarter Results

October 30, 2026

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

October 27, 2026

Enhertu approved in EU for HER2-positive eBC

October 27, 2026

Holding(s) in Company

October 26, 2026

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

October 25, 2026

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

October 24, 2026

Ultomiris approved in US in IgAN

October 22, 2026

AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes

October 20, 2026

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

October 19, 2026

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, Imfinzi, Tagrisso and Orpathys

October 19, 2026

Efzimfotase alfa showed numerical improvement in Six-Minute Walk Test achieving mean difference of 17.05 metres vs placebo in treatment-naïve adolescents and adults with hypophosphatasia at week 25 in HICKORY Phase III trial

October 11, 2026

Alexion to showcase Phase III data in hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting

October 6, 2026

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

October 5, 2026

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

October 5, 2026

AstraZeneca completes equity investment in Summit

October 5, 2026

AZ & DS collaboration with Summit for Datroway

October 2, 2026

Admission of Further Securities to Trading

October 1, 2026

Total Voting Rights

October 1, 2026

AstraZeneca announces equity investment in Summit

September 29, 2026

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer

September 28, 2026

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

September 25, 2026

AstraZeneca: Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session

September 24, 2026

Trixeo approved in EU for asthma

September 23, 2026

Klygefa recommended for EU approval by CHMP

September 21, 2026

Enhertu recommended for approval in EU in early BC

September 21, 2026

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer

September 18, 2026

Update on SERENA-4 Phase III trial

September 14, 2026

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

September 13, 2026

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

September 13, 2026

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

September 13, 2026

Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer

September 11, 2026

Imfinzi+Imdelltra improved OS in small cell lung

September 8, 2026

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

September 8, 2026

Etcamah approved in the US for HR+ breast cancer

September 7, 2026

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

September 4, 2026

Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

September 4, 2026

Admission to Trading - €2.55 billion bond offering

September 1, 2026

Enhertu approved in EU for 1L HER2-positive mBC

September 1, 2026

AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer

September 1, 2026

AstraZeneca completes agreement for Zegfrovy

September 1, 2026

Tagrisso + Orpathys improved PFS in 1L EGFRm lung

September 1, 2026

TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints

August 27, 2026

Tezspire CROSSING trial met primary endpoints

August 27, 2026

AstraZeneca prices a €2.55 billion bond offering

August 25, 2026

ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise

August 18, 2026

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

August 17, 2026

Enhertu improved PFS in 1L HER2m lung cancer

August 17, 2026

Update on eVOLVE-Lung02 Phase III trial

August 17, 2026

Tagrisso+Orpathys improved PFS & OS in EGFRm lung

August 17, 2026

Datroway approved in EU for TNBC

July 31, 2026

Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 239 decks. Every deck is listed under its year.